 |
| Global Lung Cancer Diagnostic And Screening Market Size |
Lung cancer diagnostic and screening products help to detect the presence of
cancer in the lungs at an early stage. These include imaging tests that can
detect lung abnormalities and biopsy procedures to analyze lung tissue samples.
Early detection improves treatment effectiveness and survival rates of lung
cancer patients.
The global
Lung Cancer Diagnostic And Screening Market is estimated to be valued at US$ 2458.7 Mn in 2023 and is expected
to exhibit a CAGR of 10.1% over the
forecast period 2023 to 2030, as highlighted in a new report published by
Coherent Market Insights.
Market key trends:
Rising adoption of nanoparticles-based screening is driving the growth of the
lung cancer diagnostic and screening market. Nanoparticles are being widely
used to develop new approaches for lung cancer screening and diagnostics. For
instance, gold nanoparticles are being utilized to develop tests to detect
tumor-specific proteins and tumor DNA in blood or sputum samples. They enhance
the sensitivity and specificity of screening and diagnostic tests. Researchers
are also exploring the use of nanoparticles as carriers for targeted drug
delivery to lung cancer sites post-detection. This reduces toxicity and
enhances therapeutic efficacy.
Segment Analysis
The global lung cancer diagnostic and screening market is segmented on the
basis of type, product, end user and region. Based on type, the market is
segmented into non-small cell lung cancer (NSCLC) and small cell lung cancer
(SCLC). The non-small cell lung cancer (NSCLC) segment dominates the market due
to its higher prevalence rate. NSCLC accounts for around 85% of all lung cancer
cases.
Key Takeaways
Market size
The Global
Lung Cancer Diagnostic And Screening Market Size is expected to witness
high growth, exhibiting CAGR of 10.1% over the forecast period, due to
increasing prevalence of lung cancer worldwide. According to GLOBOCAN
estimates, lung cancer burden has risen to 2.21 million new cases in 2020 from
1.80 million new cases in 2018.
Regional analysis
Regionally, North America dominates the lung cancer diagnostic and screening
market and is expected to continue its dominance over the forecast period. This
is attributed to increasing funding from public and private bodies for lung
cancer research, rising awareness regarding early diagnosis and screening, and
significant per capita healthcare spending in the region.
Key players
Key players operating in the lung cancer diagnostic and screening market are
Abbott, Illumina, Inc., Thermo Fischer Scientific, QIAGEN, Quest Diagnostics
Incorporated, NeoGenomics, NanoString, Myriad Genetics Inc. , F. Hoffmann-La
Roche Ltd, Danaher, Agilent Technologies, Inc., AstraZeneca, Sanofi, and
Janssen Pharmaceuticals, Inc. These players are focusing on developing
innovative diagnostic and screening technologies to gain a competitive edge in
the market.
Get
More Insights On This Topic: https://www.pressreleasebulletin.com/lung-cancer-diagnostic-and-screening-market-size/